

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Emerald Health Therapeutics, Inc. (the "Issuer").

Trading Symbol: EMH

Number of Outstanding Listed Securities: 213,472,095 (Aug. 31, 2021)

Date: September 10, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Issuer Response: Updates about the Company's business are available under the Company's profile on SEDAR at www.sedar.com and on Emerald Health Therapeutics' investors website at emeraldhealth.ca/investors.

On August 06, 2021, the Issuer announced that Avtar Dhillon, MD, has resigned from his roles as director and Executive Chairman of Emerald's board of directors for personal reasons effective as of the date of the announcement. Jim Heppell was appointed Chairman of the board of directors. On August 11th, the company provided additional details regarding the resignation of Dr. Avtar Dhillon as director and executive chairman.

On August 10, 2021, the Issuer announced that it appointed Nick Mosgrove as VP Sales & Marketing.

On August 31, 2021, the issuer announced that it reported its financial results for the three and six months ended June 30, 2021, after the market close on August 30, 2021. Full versions of Emerald's unaudited condensed interim consolidated financial statements and management discussion and analysis can be found on www.sedar.com.

Please refer to the Issuer's news releases dated August 06th, 10th, 11th and 31st.

2. Provide a general overview and discussion of the activities of management.

Issuer Response: The Issuer's Management continues to focus on building a sustainable and profitable business by executing on its growth strategy encompassing marketing and sales, product development, and global growth opportunities. Management has been actively involved in managing operations, optimizing its asset base, acquiring talent, overseeing new product development initiatives and pursuing new business initiatives.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Issuer Response: None noted.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Issuer Response: None noted.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Issuer Response: None noted.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Issuer Response: None noted.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Issuer Response: None noted.

8. Describe the acquisition of new customers or loss of customers.

Issuer Response: Aside from the acquisition or loss of individual medical patient customers in the normal course of business, the Issuer has no further customer acquisitions or losses to report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Issuer Response: None noted.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Issuer Response: The issuer appointed Nick Mosgrove as VP Sales & Marketing. Aside from the hiring or termination of employees in the normal course of business, the Issuer has no further hirings or terminations to report.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Issuer Response: None noted.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Issuer Response: None noted.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Issuer Response: None noted.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	150,000	RSUs settled	N/A
Options for Common Shares	225,000	Options granted to employees and management	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

Issuer Response: None noted.

15. Provide details of any loans to or by Related Persons.

Issuer Response: None noted.

16. Provide details of any changes in directors, officers or committee members.

Issuer Response: On August 6, 2021, the Company announced that Avtar Dhillon resigned from his roles as director and Executive Chairman of the board of directors of the Company and its subsidiaries. Jim Heppell was appointed Chairman of the board of directors.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Issuer Response: The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Listing Statement dated April 26, 2021, under the heading "Risk Factors"; in the Issuer's most recently filed management's discussion and analysis; and in the Issuer's other public filings, all of which are available under the Issuer's SEDAR profile at www.sedar.com, and which are incorporated into this report by reference thereto.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated Sep 10, 2021.

Jenn Hepburn
 Name of Director or Senior
 Officer

/s/ Jenn Hepburn
 Signature
 Chief Financial Officer
 Official Capacity

Issuer Details Name of Issuer Emerald Health Therapeutics, Inc.	For Month End 21/08/31	Date of Report YY/MM/D 21/09/10
Issuer Address Suite 210 – 800 West Pender Street		
City/Province/Postal Code Vancouver, British Columbia V6C 1J8	Issuer Fax No. (855) 624 3325	Issuer Telephone No. (800) 757-3536
Contact Name Jenn Hepburn	Contact CFO	Contact Telephone No. (800) 757-3536
Contact Email Address invest@emeraldhealth.ca	Web Site Address www.emeraldhealth.ca	

FORM 7 – MONTHLY PROGRESS REPORT